Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07254078

Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension

The goal of this observational study is to gather information on background, medical history, symptoms and physical condition, treatment options of people with chronic thromboembolic pulmonary hypertension in real clinical practice in Russia.

The main question it aims to answer is:

Which factors most influence the prognosis of participants?

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Medical Research Center of Cardiology after academician E.I. Chazov

Moscow, Russia

Location status: Recruiting

Location contact

Ekaterina O Dinevich

SUB_INVESTIGATOR

Galina V Schelkova

CONTACT

[email protected]

+74954146270

Galina V Schelkova, PhD

SUB_INVESTIGATOR

Irina E Chazova, D. Sci. (Med.)

PRINCIPAL_INVESTIGATOR

Nikolay M Danilov, D. Sci. (Med.)

PRINCIPAL_INVESTIGATOR

Sergey Y Yarovoy, PhD

SUB_INVESTIGATOR

About this study

Data from international CTEPH registries indicate variable utilization rates of available treatment options. Considering the presence of national specificities in the management of CTEPH patients, coupled with the relatively low prevalence of the disease, which poses challenges for data accumulation and research, new registry POLET (Registry of Patients with chrOnic thombomboLic pumonary hypErTension) is established to investigate CTEPH patients in real-world clinical practice.

Registry Aim:

To investigate the prognosis of patients with chronic thromboembolic pulmonary hypertension based on demographic, anamnestic, clinical characteristics, and treatment regimens.

Registry Objectives:

To describe the key demographic, anamnestic, and clinical characteristics of CTEPH patients in Russia.

To identify factors influencing the frequency of hospitalizations due to clinical deterioration in CTEPH patients.

To determine the impact of anamnestic data and treatment regimens on patient prognosis (time to clinical deterioration/death).

To determine the impact of demographic and clinical characteristics on patient survival and prognosis (time to clinical deterioration/death).

Currently, preliminary retrospective data have been collected on 300 CTEPH patients, each with 1 to 15 hospitalizations at the National Medical Research Center of Cardiology named after Academician E.I. Chazov of the Ministry of Health of Russia from 2012-2024, and who are eligible for inclusion in the registry. 200 patients will be enrolled prospectively.

The following data to be extracted from electronic medical records:

Medical History Data; Clinical Characteristics and Results of Investigations and Treatments During Each Patient Hospitalization; Operability Assessment Results; PAH-Specific Therapy, Anticoagulant Therapy, Supportive Therapy: Therapy Adjustment, Doses, Presence of Side Effects; Details of Pulmonary endarterectomy; Details of BPA performed; Patient outcomes including survival. Statistical data processing will be performed using RStudio and the R programming language. Missing data will be handled with imputation approach.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence of a confirmed diagnosis of CTEPH

Exclusion criteria

  • Presence of pulmonary hypertension of a different etiology than CTEPH

Treatment and study plan

Pulmonary endarterectomy

Procedure

A surgical procedure to remove chronic blood clots from the pulmonary arteries

Other names: PEA, PTE, Pulmonary thromboendarterectomy

Balloon pulmonary angioplasty

Procedure

A minimally invasive procedure used to treat chronic thromboembolic pulmonary hypertension by dilatating narrowed pulmonary arteries and improving blood flow to the lungs

Other names: BPA

Pulmonary hypertension-specific therapy

Drug

Medical treatment with any PH-specific drugs

Other names: PH-specific therapy, PH-Targeted Medical Therapy

Primary outcomes

  1. All-cause mortality

    Time frame: Up to 5 years

Secondary outcomes

  1. All-cause mortality

    Time frame: Up to 10 years

  2. Change in distance in 6-minute walk test

    Time frame: 1 year

  3. Change in mPAP

    Time frame: 1 year

    mPAP assesed during right heart catheterization

Sponsors and collaborators

Lead sponsor

Irina E. Chazova

Other Gov

Registry information

Official study title

Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Russia: Determinants of Long-term Outcomes in Real Clinical Practice

Acronym: POLET

Important dates

Study start
2025
Primary completion
2035
Study completion
2035
First posted
Nov 28, 2025
Registry last updated
Dec 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.